Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. September 2025 05:00 ET | Quelle: Scenic Biotech

Scenic Biotech Appoints Dr. Roland W. Bürli as CSO to Advance Pipeline of Modifier Therapies in Neuro- and Metabolic Diseases

Scenic Biotech taps Dr. Bürli as Chief Scientific Officer to lead development of innovative drug candidate pipeline fueled by the company’s Cell-Seq platform. Amsterdam, the Netherlands, September...
03. September 2025 11:14 ET | Quelle: Scenic Biotech

Scenic Biotech Publishes Novel Drug Target for Mitochondrial and Cardiac Disease in Nature

Second Nature publication in 3 months highlights strength of Scenic’s proprietary Cell-Seq platform to identify modifier genes that positively influence disease severity Amsterdam, the Netherlands,...
26. August 2025 05:00 ET | Quelle: Scenic Biotech

Scenic Enters License and Research Agreement with Alnylam

Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with Alnylam Pharmaceuticals, Inc....
07. Mai 2025 11:01 ET | Quelle: Scenic Biotech

Scenic Biotech Announces Nature Publication on the Discovery of Drug Target PLA2G15, a Modifier in Lysosomal Disease

In collaboration with a Stanford University research team, Scenic Biotech identified and characterized PLA2G15 as a novel target in lysosomal storage diseases Amsterdam, the Netherlands, May 07,...